Polifarmacia en pacientes con fibrilación auricular que reciben apixaban versus warfarina

GBD 2013 Mortality and Causes of Death Collaborators. Global, regional, and national age-sex specific all-cause and cause-specific mortality for 240 causes of death, 1990-2013: a systematic analysis for the Global Burden of Disease Study 2013. Lancet2015;385:117-71. doi:10.1016/S0140-6736(14)61682-2 pmid:25530442.

Nieuwlaat R, Olsson SB, Lip GYH, et al. Euro Heart Survey Investigators Euro Heart Survey on Atrial Fibrillation. Guideline-adherent antithrombotic treatment is associated with improved outcomes compared with undertreatment in high-risk patients with atrial fibrillation. Am Heart J2007;153:1006-12. doi:10.1016/j.ahj.2007.03.008 pmid:17540203.

Scowcroft AC, Lee S, Mant J. Thromboprophylaxis of elderly patients with AF in the UK: an analysis using the General Practice Research Database (GPRD) 2000-2009. Heart2013;99:127-32. doi:10.1136/heartjnl-2012-302843 pmid:23086966.

Singh S, Bajorek B. Pharmacotherapy in the ageing patient: the impact of age per se (a review). Ageing Res Rev2015;24:99-110. doi:10.1016/j.arr.2015.07.006 pmid:26226330.

Jyrkkä J, Enlund H, Korhonen MJ, Sulkava R, Hartikainen S. Patterns of drug use and factors associated with polypharmacy and excessive polypharmacy in elderly persons: results of the Kuopio 75+ study: a cross-sectional analysis. Drugs Aging2009;26:493-503. doi:10.2165/00002512-200926060-00006 pmid:19591524.

Gnjidic D, Hilmer SN, Blyth FM, et al. Polypharmacy cutoff and outcomes: five or more medicines were used to identify community-dwelling older men at risk of different adverse outcomes. J Clin Epidemiol2012;65:989-95. doi:10.1016/j.jclinepi.2012.02.018 pmid:22742913.

Herr M, Robine JM, Pinot J, Arvieu JJ, Ankri J. Polypharmacy and frailty: prevalence, relationship, and impact on mortality in a French sample of 2350 old people. Pharmacoepidemiol Drug Saf2015;24:637-46. doi:10.1002/pds.3772 pmid:25858336.

Wang R, Chen L, Fan L, et al. Incidence and effects of polypharmacy on clinical outcomes among patients aged 80+: a five-year follow-up study. PLoS One2015;10:e0142123. doi:10.1371/journal.pone.0142123 pmid:26554710.

Proietti M, Raparelli V, Olshansky B, Lip GYH. Polypharmacy and major adverse events in atrial fibrillation: observations from the AFFIRM trial. Clin Res Cardiol2016;105:412-20. doi:10.1007/s00392-015-0936-y pmid:26525391.

Piccini JP, Hellkamp AS, Washam JB, et al. Polypharmacy and the efficacy and safety of rivaroxaban versus warfarin in the prevention of stroke in patients with nonvalvular atrial fibrillation. Circulation2016;133:352-60. doi:10.1161/CIRCULATIONAHA.115.018544 pmid:26673560.

Abdelhafiz AH, Wheeldon NM. Risk factors for bleeding during anticoagulation of atrial fibrillation in older and younger patients in clinical practice. Am J Geriatr Pharmacother2008;6:1-11. doi:10.1016/j.amjopharm.2008.03.005 pmid:18396243.

Kagansky N, Knobler H, Rimon E, Ozer Z, Levy S. Safety of anticoagulation therapy in well-informed older patients. Arch Intern Med2004;164:2044-50. doi:10.1001/archinte.164.18.2044 pmid:15477441.

Donzé J, Clair C, Hug B, et al. Risk of falls and major bleeds in patients on oral anticoagulation therapy. Am J Med2012;125:773-8. doi:10.1016/j.amjmed.2012.01.033 pmid:22840664.

Leiss W, Méan M, Limacher A, et al. Polypharmacy is associated with an increased risk of bleeding in elderly patients with venous thromboembolism. J Gen Intern Med2015;30:17-24. doi:10.1007/s11606-014-2993-8 pmid:25143224.

Goldhaber SZ, Eriksson H, Kakkar A, et al. Influence of polypharmacy on the efficacy and safety of dabigatran versus warfarin for the treatment of acute venous thromboembolism: a pooled analysis of RE-COVER and RE-COVER II. Circulation2015;132:A12422.
    ↵ Stroke Prevention in Atrial Fibrillation Investigators. Bleeding during antithrombotic therapy in patients with atrial fibrillation. Arch Intern Med1996;156:409-16. doi:10.1001/archinte.1996.00440040081009 pmid:8607726.
    CrossRefMedlineWeb of Science
    ↵Wehinger C, Stöllberger C, Länger T, Schneider B, Finsterer J. Evaluation of risk factors for stroke/embolism and of complications due to anticoagulant therapy in atrial fibrillation. Stroke2001;32:2246-52. doi:10.1161/hs1001.097090 pmid:11588308.

Connolly SJ, Eikelboom J, Joyner C, et al. AVERROES Steering Committee and Investigators. Apixaban in patients with atrial fibrillation. N Engl J Med2011;364:806-17. doi:10.1056/NEJMoa1007432 pmid:21309657.

Granger CB, Alexander JH, McMurray JJV, et al. ARISTOTLE Committees and Investigators. Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med2011;365:981-92. doi:10.1056/NEJMoa1107039 pmid:21870978.

Halvorsen S, Atar D, Yang H, et al. Efficacy and safety of apixaban compared with warfarin according to age for stroke prevention in atrial fibrillation: observations from the ARISTOTLE trial. Eur Heart J2014;35:1864-72. doi:10.1093/eurheartj/ehu046 pmid:24561548.

Nobili A, Marengoni A, Tettamanti M, et al. Association between clusters of diseases and polypharmacy in hospitalized elderly patients: results from the REPOSI study. Eur J Intern Med2011;22:597-602. doi:10.1016/j.ejim.2011.08.029 pmid:22075287.